Actos, Pioglitazone Newswire

Actos, Pioglitazone Newswire

Comprehensive Real-Time News Feed for Actos, Pioglitazone (generic).

Results 1 - 20 of 42 in Actos, Pioglitazone (generic)

  1. Poxel Announces Participation at the H.C. Wainwright 20th Annual Global Investment ConferenceRead the original story w/Photo

    Monday Sep 3 | Business Wire

    The H.C. Wainwright 20th Annual Global Investment Conference is being held on September 4-6th at The St. Regis Hotel in New York City. The Company will present a corporate overview on Thursday, September 6th from 10:00-10:25 AM ET in Louis XVI A room on the 2nd floor and will be available to participate in one-on-one meetings with investors.

    Comment?

  2. Effects on the incidence of cardiovascular events of the addition of...Read the original story

    Thursday Aug 30 | CiteULike

    Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin : a randomised, multicentre trial. The best treatment option for patients with type 2 diabetes in whom treatment with metformin alone fails to achieve adequate glycaemic control is debated.

    Comment?

  3. [Newer anti - diabetic therapies and chronic kidney disease].Read the original story

    Wednesday Aug 29 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. Worldwide, an estimated 200 million people have chronic kidney disease , whose most common causes include hypertension, arteriosclerosis, and diabetes.

    Comment?

  4. Amphetamines don't improve motor recovery after strokeRead the original story w/Photo

    Tuesday Aug 28 | PhysOrg Weblog

    A pilot clinical trial exploring the benefit of d-amphetamine combined with physical therapy for stroke patients found no evidence that the regimen improved post-stroke motor recovery. The results, published in the Aug. 27, 2018 issue of JAMA Neurology , are "another step to better understand an approach that may or may not eventually lead to a new way of improving recovery," said Dr. Larry Goldstein, chair of the University of Kentucky Department of Neurology and the study's lead author.

    Comment?

  5. Data Projects the NASH Market Will Eclipse USD 21 Billion by 2025Read the original story

    Aug 13, 2018 | Newkerala.com

    NEW YORK: According to a report published by Allied Market Research, the global non-alcoholic steatohepatitis market was valued at USD 1,179 Million in 2017 and is expected to reach USD 21,478 Million by 2025 while growing at a CAGR of 58.4pc from 2021 to 2025. NASH is a common liver disease, often called as silent liver disease.

    Comment?

  6. Doctors admit that scientific evidence questioning the safety of...Read the original story w/Photo

    Aug 1, 2018 | NewsTarget.com

    As type 2 diabetes continues its meteoric rise around the world, researchers are working overtime in search of better treatments - and sometimes their findings are ignored by profit-minded pharmaceutical companies. Some people believe that the most important thing that diabetics can do is to lower their glucose at all costs.

    Comment?

  7. Imaging method reveals Parkinson's heart damage, possible treatmentRead the original story w/Photo

    Jul 16, 2018 | UPI

    Researchers found a possible treatment for heart damage cause by Parkinson's, after finding that an imaging method could reveal and allow for treatment evaluation. A way to track the mechanisms that cause damage to heart nerve cells was tested in rhesus macaque monkeys' human-like nervous system and heart.

    Comment?

  8. Researchers trace Parkinson's damage in the heartRead the original story

    Jul 13, 2018 | Science Daily

    A new way to examine stress and inflammation in the heart will help Parkinson's researchers test new therapies and explore an unappreciated way the disease puts people at risk of falls and hospitalization. A new way to examine stress and inflammation in the heart will help Parkinson's researchers test new therapies and explore an unappreciated way the disease puts people at risk of falls and hospitalization.

    Comment?

  9. UW-Madison researchers develop new method to track Parkinson's damage in the heartRead the original story w/Photo

    Jul 13, 2018 | Medical News

    A new way to examine stress and inflammation in the heart will help Parkinson's researchers test new therapies and explore an unappreciated way the disease puts people at risk of falls and hospitalization. By the time Parkinson's disease patients are diagnosed -- typically based on the tremors and motor-control symptoms most associated with the disease -- about 60 percent of them also have serious damage to the heart's connections to the sympathetic nervous system.

    Comment?

  10. What is pregabalin?Read the original story w/Photo

    Jul 11, 2018 | Medical News Today

    Healthline Media, Inc. would like to process and share personal data and data about your use of our site with our third party partners using cookies and similar automatic collection tools in order to a) personalize content and/or offers on our site or other sites, b) communicate with you upon request, and/or c) for additional reasons upon notice and, when applicable, with your consent. Healthline Media, Inc. is based in and operates this site from the United States.

    Comment?

  11. Heart Failure After Ischemic Stroke or TIA in Insulin-Resistant...Read the original story

    Jun 22, 2018 | Circulation

    The Insulin Resistance Intervention after Stroke trial demonstrated that pioglitazone reduced risk for both cardiovascular events and diabetes in insulin resistant patients. However, concern remains that pioglitazone may increase risk for heart failure in susceptible individuals.

    Comment?

  12. Do sulphonylureas still have a place in clinical practice?Read the original story

    Jun 10, 2018 | CiteULike

    Sulphonylureas have been commercially available since the 1950s, but their use continues to be associated with controversy. Although adverse cardiovascular outcomes in some observational studies have raised concerns about sulphonylureas, findings from relatively recent, robust, and high-quality systematic reviews have indicated no increased risk of all-cause mortality associated with sulphonylureas compared with other active treatments.

    Comment?

  13. Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.Read the original story

    Jun 10, 2018 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. It is known that Cardiovascular disease is the leading cause of morbidity and mortality in individuals with type 2 diabetes.

    Comment?

  14. What to know about bladder polypsRead the original story w/Photo

    Jun 5, 2018 | Medical News Today

    Bladder polyps are small, often cauliflower-like growths that protrude from the lining of the urinary bladder where a person stores urine. Typically, polyps are groups of abnormal cells that appear along mucous membranes in the body, though they can appear almost anywhere.

    Comment?

  15. Diabetes Drug Market Scenario, Leading Players, Segments Analysis and Growth Drivers to 2023Read the original story w/Photo

    Apr 27, 2018 | SBWire

    The Global Diabetes Drug Market is expected to grow at a CAGR of 6.38% during forecasted period 2018 -2023. The consumption of Diabetes Drugs is increasing owing to the rising prevalence of diabetes in various age groups.

    Comment?

  16. The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions.Read the original story

    Apr 22, 2018 | CiteULike

    Diabetes and heart failure are both global epidemics with tremendous costs on society with increased rates of HF hospitalizations and worsened prognosis when co-existing, making it a significant "deadly duo." The evidence for pharmacological treatment of HF in patients with type 2 diabetes mellitus stems typically from either subgroup analyses of patients that were recruited to randomized controlled trials of HF interventions, usually in patients with reduced ejection fraction , or from subgroup analyses of HF patients recruited to cardiovascular outcome trials of glucose lowering agents involving patients with T2DM.

    Comment?

  17. Current and future pharmacological therapies for NAFLD/NASH.Read the original story

    Apr 17, 2018 | CiteULike

    Nonalcoholic fatty liver disease is the most prevalent liver disease worldwide, and there is no approved pharmacotherapy. The efficacy of vitamin E and pioglitazone has been established in nonalcoholic steatohepatitis , a progressive form of NAFLD.

    Comment?

  18. Type 2 diabetes mellitus and heart failure: a position statement from ...Read the original story

    Apr 15, 2018 | CiteULike

    Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. The coexistence of type 2 diabetes mellitus and heart failure , either with reduced or preserved ejection fraction , is frequent and associated with a higher risk of HF hospitalization, all-cause and cardiovascular mortality.

    Comment?

  19. Changes To The 2019 Part D Coverage GapRead the original story w/Photo

    Apr 9, 2018 | The Post-Journal, Jamestown New York

    Question: I just picked up my medication and the cost changed? It is a different amount than it has been, what happened? The clerk told me I hit the coverage gap.

    Comment?

  20. Free diabetes medications for a year at area pharmacies from Blink HealthRead the original story w/Photo

    Apr 9, 2018 | South Florida Sun-Sentinel

    Publix has expanded on community service with a new low-price prescription drug program . Pharmacies now offer 90-day supplies of 29 generic medications for $7.50.

    Comment?